ORLANDO, FL—The direct thrombin inhibitor bivalirudin protects patients with non-ST-elevation acute myocardial infarction (NSTEMI) from severe adverse events as well as a combination of abciximab and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback